Deaths and Cardiovascular Events in Men Receiving Testosterone (original) (raw)

A controversial study by Vigen et al. reported increased deaths and cardiovascular events in men receiving testosterone therapy, contradictory to two decades of literature. The authors argue that this study's retrospective design and flawed data misrepresent the safety of testosterone therapy. Key issues highlighted include inadequate definitions of therapy duration and patient monitoring, and a mean testosterone level indicating potential undertreatment. The response emphasizes the importance of appropriate study design and accurate patient exclusions in assessing testosterone's risks and benefits.